Toxic shock syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(16 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{{Infobox_Disease |
__NOTOC__
  Name          = {{PAGENAME}} |
{{About1|Staphylococcus aureus}}
  Image          = |
{{Seealso|Streptococcus pyogenes}}
  Caption        = |
 
  DiseasesDB    = 13187 |
{{Toxic shock syndrome}}
  ICD10          = {{ICD10|A|48|3|a|30}} |
  ICD9          = {{ICD9|040.82}} |
  ICDO          = |
  OMIM          = |
  MedlinePlus    = |
  MeshID        = D012772 |
}}
{{SI}}
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''


{{CMG}}
{{CMG}}; {{AE}} {{HK}}, {{MIR}}
 
{{Editor Help}}
 
==Overview==
'''Toxic shock syndrome''' ('''TSS''') is a rare but potentially fatal disease caused by a [[Exotoxin|bacterial toxin]]. Different [[bacterium|bacteria]]l [[toxins]] may cause toxic shock syndrome, depending on the situation. The causative agents are the [[Gram-positive]] bacteria ''[[Staphylococcus aureus]]'' and ''[[Streptococcus pyogenes]]''. Streptococcal TSS is sometimes referred to as '''Toxic Shock Like Syndrome''' ('''TSLS''').
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/toxicshock_t.htm
 
==Pathogenesis==
 
In both TSS (caused by S. aureus) and TSLS (caused by S. pyogenes), disease progression stems from a [[superantigen]] toxin that allows the non-specific binding of MHC II with [[T cell]] receptors, resulting in polyclonal T-cell activation.
 
Usually exotoxin producing strains of Staphylococcus aureus, a bacterium. S. aureus commonly colonizes skin and mucous membranes in humans. TSS has been associated with use of tampons and intravaginal contraceptive devices in women and occurs as a complication of skin abscesses or surgery.
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/toxicshock_t.htm
 
== Risk Factors ==
 
Menstruating women, women using barrier contraceptive devices, persons who have undergone nasal surgery, and persons with postoperative staphylococcal wound infections.
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/toxicshock_t.htm
 
==Routes of infection==
 
This infection can occur via the [[skin]] (e.g. cuts, surgery, burns), [[vagina]] (via [[tampon]]), or [[pharynx]].  However, most of the large number of individuals who are exposed to or colonized with toxin-producing strains of ''[[Staphylococcus aureus|S. aureus]]'' or ''[[Streptococcus pyogenes|S. pyogenes]]'' do not develop toxic shock syndrome.  One reason is that a large fraction of the population has protective antibodies against the toxins that cause TSS.<ref>{{cite journal |author=McCormick J, Yarwood J, Schlievert P |title=Toxic shock syndrome and bacterial superantigens: an update |journal=Annu Rev Microbiol |volume=55 |issue= |pages=77-104 |year= |pmid=11544350}}</ref>  It is not clear why the antibodies are present in people who have never had the disease.
 
The number of reported staphylococcal toxic shock syndrome cases has decreased significantly in recent years. Approximately half the cases of staphylococcal TSS reported today are associated with tampon use during [[menstruation]], usually in young women, though TSS also occurs in children, men, and non-menstruating women. In the US in 1997, only five confirmed menstrual-related TSS cases were reported, compared with 814 cases in 1980, according to data from the [[Centers for Disease Control and Prevention]] (CDC).<ref name="CDRH1999">Center for Devices and Radiological Health, U.S. Food and Drug Administration, Consumer information (Jul 23, 1999) [http://www.fda.gov/cdrh/consumer/tamponsabs.html Tampons and Asbestos, Dioxin, & Toxic Shock Syndrome] [http://www.fda.gov/cdrh/consumer/tamponsabs.pdf PDF]</ref>  It has been estimated that each year 1 to 17 of every 100,000 menstruating females will get TSS.<ref name="Stayfree-TSS">{{cite web | year = 2006 | url = http://www.stayfree.com/faq_TSS.jsp| title = Stayfree - FAQ About Toxic Shock Syndrome (TSS) | accessdate = 2006-10-13}}</ref>
 
Although scientists have recognized an association between TSS and tampon use, no firm causal link has been established. Research conducted by the CDC suggested that use of some high absorbency tampons increased the risk of TSS in menstruating women. A few specific tampon designs and high absorbency tampon materials were also found to have some association with increased risk of TSS.  These products and materials are no longer used in tampons sold in the U.S. (The materials include [[polyester]], [[carboxymethylcellulose]] and [[polyacrylate]]).<ref name="Collegian2003-Citrinbaum">{{cite web | author = Citrinbaum, Joanna | year =Oct. 14, 2003 | url=http://www.collegian.psu.edu/archive/2003/10/10-14-03tdc/10-14-03dscihealth-01.asp | title =The question's absorbing: 'Are tampons little white lies?' | work = The Digital Collegian | accessdate =2006-03-20 }}</ref>
Tampons made with [[rayon]] do not appear to have a higher risk of TSS than cotton tampons of similar absorbency.<ref>{{cite journal |author=Parsonnet J, Modern P, Giacobbe K |title=Effect of tampon composition on production of toxic shock syndrome toxin-1 by ''Staphylococcus aureus'' in vitro |journal=J Infect Dis |volume=173 |issue=1 |pages=98-103 |year=1996 |pmid=8537689}}</ref>
 
Toxin production by ''S. aureus'' requires a protein-rich environment, which is provided by the flow of menstrual blood, a neutral vaginal pH, which occurs during menstruation, and elevated oxygen levels, which is provided by the tampon that is inserted into the normally anaerobic vaginal environment.<ref>{{cite journal |author=McCormick J, Yarwood J, Schlievert P |title=Toxic shock syndrome and bacterial superantigens: an update |journal=Annu Rev Microbiol |volume=55 |issue= |pages=77-104 |year= |pmid=11544350}}</ref>  Although ulcerations have been reported in women using super absorbent tampons, the link to menstrual TSS, if any, is unclear.  The toxin implicated in menstrual TSS is capable of entering the bloodstream by crossing the vaginal wall in the absence of ulcerations.<ref>{{cite journal |author=Schlievert P, Jablonski L, Roggiani M, Sadler I, Callantine S, Mitchell D, Ohlendorf D, Bohach G |title=Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals |journal=Infect Immun |volume=68 |issue=6 |pages=3630-4 |year=2000 |pmid=10816521}}</ref>  Women may avoid problems by choosing a tampon with the minimum absorbency needed to control menstrual flow and using tampons only during active menstruation. Alternately, a woman may choose to use a different kind of menstrual product that may eliminate or reduce the risk of TSS, such as [[sanitary napkins]] or a [[menstrual cup]].
 
==History==
===Initial description of toxic shock syndrome===
 
The term ''toxic shock syndrome'' was first used in 1978 by a Denver pediatrician, Dr. J.K. Todd, to describe the staphylococcal illness in three boys and four girls aged 8-17 years.<ref>{{cite journal |author=Todd J, Fishaut M, Kapral F, Welch T |title=Toxic-shock syndrome associated with phage-group-I staphylococci |journal=Lancet |volume=2 |issue=8100 |pages=1116-1118 |year=1978 |pmid=82681}}</ref>  Even though ''S. aureus'' was isolated from mucosal sites from the patients, bacteria could not be isolated from the blood, cerebrospinal fluid, or urine, raising suspicion that a toxin was involved.  The authors of the study noted that reports of similar staphylococcal illnesses had appeared occasionally as far back as 1927.  Most notably, the authors at the time failed to consider the possibility of a connection between toxic shock syndrome and tampon use, as three of the girls who were menstruating when the illness developed were using tampons.<ref>{{cite journal |author=Todd J |title=Toxic shock syndrome--scientific uncertainty and the public media |journal=Pediatrics |volume=67 |issue=6 |pages=921-923 |year=1981 |pmid=7232057}}</ref>
 
===Rely tampons===
Following a controversial period of test marketing in Rochester, New York and Fort Wayne, Indiana<ref name="MUM-Rely">{{cite web|author=Finley, Harry|url=http://www.mum.org/Rely.htm|title=Rely Tampon: It Even Absorbed the Worry!|work=Museum of Menstruation|accessdate=2006-03-20}}</ref>, in August of 1978 Procter and Gamble introduced superabsorbent Rely tampons to the United States market<ref>{{cite journal|author=Hanrahan S|title=Historical review of menstrual toxic shock syndrome|journal=Women Health|volume=21|issue=2-3|pages=141-65|year=1994|pmid=8073784}}</ref> in response to women's demands for tampons that could contain an entire menstrual flow without leaking or replacement.<ref name="Collegian2003-Citrinbaum"/> Rely used [[Carboxymethyl cellulose|carboxymethylcellulose]] (CMC) and compressed beads of [[polyester]] for absorption. This tampon design could absorb nearly 20 times its own weight in fluid<ref name="TTS1997-Vitale">{{cite web|author=Vitale, Sidra|year=1997|url=http://www.io.com/~wwwomen/menstruation/tss.html|title=Toxic Shock Syndrome|publisher=Web by Women, for Women|accessdate=2006-03-20}}</ref>. Further, the tampon would "blossom" into a cup shape in the vagina in order to hold menstrual fluids.


In January 1980, epidemiologists in Wisconsin and Minnesota reported the appearance of TSS, mostly in menstruating women, to the CDC.<ref>CDC 1980. "Toxic-shock syndrome--United States." ''MMWR'' '''29'''(20):229-230.</ref>  [[S. aureus]] was successfully cultured from most of the women.  A CDC task force investigated the epidemic as the number of reported cases rose throughout the summer of 1980, accompanied by widespread publicity.  In September 1980, the CDC reported that users of Rely were at increased risk for developing TSS.<ref>CDC 1980.  "Follow-up on toxic-shock syndrome." ''MMWR'' '''29'''(37):441-445.</ref>
{{SK}} Staphylococcal toxic shock syndrome, TSS, toxic shock-like syndrome, TSLS, Menstrual toxic shock, Toxic shock


On September 22, 1980, Procter and Gamble recalled Rely<ref>{{cite journal|author=Hanrahan S|title=Historical review of menstrual toxic shock syndrome|journal=Women Health|volume=21|issue=2-3|pages=141-165|year=1994|pmid=8073784}}</ref> following release of the [[Centers for Disease Control and Prevention|CDC]] report. As part of the voluntary recall, Procter and Gamble entered into a consent agreement with the FDA "providing for a program for notification to consumers and retrieval of the product from the market".<ref name="History2001-Kohen">{{cite web|author=Kohen, Jamie|year=2001|url= http://www.google.com/searchq=cache:wqVsFR5FlQwJ:leda.law.harvard.edu/leda/data/359/Kohen.rtf+rely+tampons&hl=en&gl=us&ct=clnk&cd=15|title=The History and Regulation of Menstrual Tampons|work=[http://leda.law.harvard.edu/leda/data/359/Kohen.rtf RTF document]|accessdate=2006-03-30}}</ref> However, it was clear to other investigators that Rely was not the only culprit.  Other regions of the United States saw increases of menstrual TSS before Rely was introduced.<ref>{{cite journal|author= Petitti D, Reingold A, Chin J|title=The incidence of toxic shock syndrome in Northern California. 1972 through 1983|journal= JAMA|volume=255|issue=3|pages=368-72|year=1986|pmid=3941516}}</ref> It was shown later that higher absorbency of tampons was associated with an increased the risk for TSS, regardless of the chemical composition or the brand of the tampon. The sole exception was Rely, for which the risk for TSS was still higher when corrected for its absorbency.<ref>{{cite journal |author=Berkley S, Hightower A, Broome C, Reingold A|title=The relationship of tampon characteristics to menstrual toxic shock syndrome|journal=JAMA|volume=258|issue=7|pages=917-20|year=1987|pmid=3613021}}</ref> The ability of carboxymethylcellulose to filter the ''S. aureus'' toxin that causes TSS may account for the increased risk associated with Rely.<ref name="TTS1997-Vitale"/>
==[[Toxic shock syndrome overview|Overview]]==


By the end of 1980, the number of TSS cases reported to the CDC began to decline. The reduced incidence was attributed not only to the removal of Rely from the market, but also from the diminished use of all tampon brands. According to the Boston Women's Health Book Collective, 942 women were diagnosed with tampon-related TSS in the USA from the March 1980 to March 1981, 40 of whom died.
==[[Toxic shock syndrome historical perspective|Historical Perspective]]==
==[[Toxic shock syndrome classification|Classification]]==
==[[Toxic shock syndrome pathophysiology|Pathophysiology]]==
==[[Toxic shock syndrome causes|Causes]]==
==[[Toxic shock syndrome differential diagnosis|Differentiating Toxic Shock Syndrome from other Diseases]]==


==Symptoms and diagnosis==
==[[Toxic shock syndrome epidemiology and demographics|Epidemiology and Demographics]]==


Toxic shock syndrome (TSS) is characterized by sudden onset of [[fever]], chills, [[vomiting]], [[diarrhea]], muscle aches and [[rash]]. It can rapidly progress to severe and intractable hypotension and multisystem dysfunction. Desquamation, particularly on the palms and soles can occur 1-2 weeks after onset of the illness.
==[[Toxic shock syndrome risk factors|Risk Factors]]==
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/toxicshock_t.htm
==[[Toxic shock syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]==


In general symptoms of toxic shock syndrome vary depending on the underlying cause. In either case, diagnosis is based strictly upon CDC criteria modified in 1981 after the initial surge in tampon-associated infections<ref>http://wonder.cdc.gov/wonder/prevguid/m0025629/m0025629.asp#head001e00000000000</ref>. TSS resultant of infection with the bacteria ''Staphylococcus aureus'' typically manifests in otherwise healthy individuals with high [[fever]], accompanied by low [[blood pressure]], [[malaise]] and confusion, which can rapidly progress to stupor, [[coma]], and multi-organ failure. The characteristic rash, often seen early in the course of illness, resembles a sunburn, and can involve any region of the body, including the lips, mouth, eyes, palms and soles. In patients who survive the initial onslaught of the infection, the rash ''desquamates'', or peels off, after 10–14 days.
==Diagnosis==


In contrast, TSLS is caused by the bacteria ''[[Streptococcus pyogenes]]'', and it typically presents in people with pre-existing skin infections with the bacteria. These individuals often experience severe pain at the site of the skin infection, followed by rapid progression of symptoms as described above for TSS. In contrast to TSS caused by Staphylococcus, Streptococcal TSS less often involves a sunburn-rash.
[[Toxic shock syndrome diagnostic criteria|Diagnostic Criteria]] | [[Toxic shock syndrome history and symptoms|History and Symptoms]] | [[Toxic shock syndrome physical examination|Physical Examination]] | [[Toxic shock syndrome laboratory findings|Laboratory Findings]] | [[Toxic shock syndrome x ray|X Ray]] | [[Toxic shock syndrome CT|CT]] | [[Toxic shock syndrome MRI|MRI]] | [[Toxic shock syndrome other imaging findings|Other Imaging Findings]] | [[Toxic shock syndrome other diagnostic studies|Other Diagnostic Studies]]


Diagnosis of TSS and TSLS are strictly based on CDC criteria:
==Treatment==
# [[Body temperature]] > 38.9 °C (102.02 °F)
# Systolic [[blood pressure]] < 90 mmHg
# Diffuse [[rash]], intense etheraderma, blanching ("boiled lobster") with subsequent desquamation, especially of the palms and soles
# Involvement of three or more organ systems:
#* GI ([[vomiting]], [[diarrhea]])
#* [[Mucous membrane]] [[hyperemia]] (vaginal, oral, conjunctival)
#* [[Renal failure]] ([[serum creatinine]] > 2x normal)
#* [[Liver|Hepatic]] inflammation (AST, ALT > 2x normal)
#* [[Thrombocytopenia]] (platelet count < 100,000 / mm³)
#* CNS involvement (confusion without any focal neurological findings)


== Differential Diagnosis ==
[[Toxic shock syndrome medical therapy|Medical Therapy]] | [[Toxic shock syndrome surgery|Surgery]] | [[Toxic shock syndrome primary prevention|Primary Prevention]] | [[Toxic shock syndrome secondary prevention|Secondary Prevention]] | [[Toxic shock syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Toxic shock syndrome future or investigational therapies|Future or Investigational Therapies]]
*Absence of protective immunity
*Child birth
*Infections
*Menstruation
*Nasal packing
*Staphylococcus aureus
*Streptococcus pyogenes
*Wound infection


==Therapy==
==Case Studies==
Women wearing a tampon at the onset of symptoms should remove it immediately. The severity of this disease results in hospitalization for treatment. Antibiotic treatment consists of [[penicillin]] and [[clindamycin]].
[[Toxic shock syndrome case study one|Case #1]]
 
==Related Chapters==
One of the symptoms of streptococcal toxic shock syndrome is extreme infection of the skin and deeper parts is called [[fasciitis necroticans|necrotizing fasciitis]]. This often requires prompt surgical treatment.
 
With proper treatment, patients usually recover in two to three weeks. The condition, however, can be fatal within hours. Sometimes it is required that patients are admitted to the [[intensive care unit]] for supportive care in case of [[multiple organ failure]].
 
==See also==
*[[Necrotizing fasciitis]]
*[[Necrotizing fasciitis]]
*[[Septic shock]]
*[[Septic shock]]
==References==
{{Reflist|2}}
[[Category:Disease state]]
[[Category:Syndromes]]
[[Category:Infectious disease]]


[[de:Toxisches Schocksyndrom]]
[[de:Toxisches Schocksyndrom]]
Line 117: Line 46:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Disease]]
[[Category:Syndromes]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]

Latest revision as of 00:26, 30 July 2020

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Staphylococcus aureus.

Template:Seealso

Toxic shock syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Shock Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic shock syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic shock syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic shock syndrome

CDC on Toxic shock syndrome

Toxic shock syndrome in the news

Blogs on Toxic shock syndrome

Directions to Hospitals Treating Toxic shock syndrome

Risk calculators and risk factors for Toxic shock syndrome

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2], Mahshid Mir, M.D. [3]

Synonyms and keywords: Staphylococcal toxic shock syndrome, TSS, toxic shock-like syndrome, TSLS, Menstrual toxic shock, Toxic shock

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Shock Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

de:Toxisches Schocksyndrom nl:Toxischeshocksyndroom no:Toksisk sjokksyndrom sv:Toxic shock syndrome

Template:WikiDoc Sources